Psoriasis Treatment Market Size to Hit USD 59.89 Billion by 2033

Psoriasis Treatment Market Size, Share, Growth Trends, Segmental Analysis By Drug Class (TNF Inhibitors [Adalimumab, Etanercept, Infliximab], IL-17 Inhibitors [Secukinumab, Ixekizumab, Bimekizumab], IL-23 Inhibitors [Guselkumab, Risankizumab, Tildrakizumab], TYK2 and JAK Inhibitors [Deucravacitinib, Other TYK2/JAK Inhibitors], PDE4 Inhibitors, Topical Therapies [Corticosteroids, Vitamin D Analogues, Retinoids, Other Topicals], Conventional Systemic Therapies), By Therapy Type (Biologics, Oral Small Molecule Therapies, Topical Therapies, Phototherapy, Conventional Systemic Therapies), By Disease Type (Plaque Psoriasis, Psoriatic Arthritis, Guttate Psoriasis, Inverse Psoriasis, Pustular Psoriasis, Erythrodermic Psoriasis, Other Disease Types), By Route of Administration (Oral, Injectable/Subcutaneous, Intravenous, Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Specialty Pharmacies, Online Pharmacies, Other Channels), By Region (North America [United States, Canada], Europe [Germany, United Kingdom, France, Italy, Spain, Rest of Europe], Asia Pacific [China, India, Japan, South Korea, Australia, Rest of Asia Pacific], Latin America [Brazil, Mexico, Rest of Latin America], Middle East & Africa [GCC Countries, South Africa, Rest of Middle East & Africa]), and Market Forecast, 2026 – 2033

  • Published: May, 2026
  • Report ID: 306
  • Pages: 160+
  • Format: PDF / Excel.

This report contains the Latest Market Figures, Statistics, and Data.

Get a Sample
logo

Psoriasis Treatment Market Size to Hit USD 59.89 Billion by 2033

(An Updated Version is Available)

1. Preface

  • 1.1 Report Description

  • 1.2 Research Scope & Assumptions

  • 1.3 Research Methodology & Data Sources

  • 1.4 List of Abbreviations

2. Executive Summary

  • 2.1 Market Snapshot

  • 2.2 Key Market Highlights

  • 2.3 Analyst Viewpoint & Key Findings

  • 2.4 Strategic Recommendations

3. Market Overview

  • 3.1 Market Definition & Scope

    • 3.1.1 Psoriasis — Pathophysiology, Disease Burden & Classification (PASI Scoring, BSA %, DLQI Assessment)

    • 3.1.2 Types of Psoriasis Covered in Scope (Plaque, Pustular, Erythrodermic, Guttate, Inverse, Psoriatic Arthritis)

    • 3.1.3 Treatment Landscape Overview — Topical, Systemic, Biologic & Emerging Therapies

  • 3.2 Value Chain Analysis

    • 3.2.1 Active Pharmaceutical Ingredient (API) & Biologic Substrate Suppliers (Monoclonal Antibody Manufacturing, CHO Cell Lines, Cytokine Inhibitor Synthesis)

    • 3.2.2 Drug Discovery, Pre-Clinical Development & Mechanism of Action Validation

    • 3.2.3 Clinical Trial Execution, Regulatory Submission & Product Approval

    • 3.2.4 Commercial Manufacturing, Fill-Finish & Quality Control (GMP Compliance)

    • 3.2.5 Distribution (Hospital Pharmacies, Specialty Pharmacies, Retail, Online Channels)

    • 3.2.6 End-User Prescribing (Dermatologists, Rheumatologists, Primary Care Physicians, Telehealth)

  • 3.3 Market Concentration & Characteristics

    • 3.3.1 Degree of Market Consolidation (Highly Consolidated — Top 5 Players Holding ~65–70% Revenue Share)

    • 3.3.2 Biologic vs. Non-Biologic Market Dynamics (Biologics — 90.73% Market Share in 2026)

    • 3.3.3 Innovation Intensity & R&D Investment Trends in IL Inhibitors, TYK2 & JAK Inhibitors

  • 3.4 Technology Roadmap & Innovation Pipeline

    • 3.4.1 Established Drug Technology Platforms

      • TNF-α Inhibitors (Adalimumab — Humira/Biosimilars; Etanercept — Enbrel; Infliximab — Remicade; Certolizumab Pegol — Cimzia)

      • IL-12/23 Inhibitors (Ustekinumab — Stelara; Risankizumab — Skyrizi; Guselkumab — Tremfya; Tildrakizumab — Ilumya; Mirikizumab — Omvoh)

      • IL-17A Inhibitors (Secukinumab — Cosentyx; Ixekizumab — Taltz; Bimekizumab — Bimzelx — IL-17A/F Dual Inhibitor)

      • IL-17 Receptor Inhibitors (Brodalumab — Siliq/Kyntheum)

      • Oral Phosphodiesterase-4 (PDE4) Inhibitors (Apremilast — Otezla; Roflumilast — Zoryve Cream)

      • Oral TYK2 (Tyrosine Kinase 2) Inhibitors (Deucravacitinib — Sotyktu — BMS; First-in-Class Oral Biologic-Level Efficacy)

      • Oral JAK Inhibitors (Upadacitinib — Rinvoq; Tofacitinib — Xeljanz for PsA)

      • Conventional Systemic Therapies (Methotrexate, Cyclosporine, Acitretin)

      • Topical Corticosteroids, Vitamin D Analogues, Retinoids & Calcineurin Inhibitors

      • Phototherapy (Narrowband UVB, PUVA, Excimer Laser — 308 nm)

    • 3.4.2 Emerging & Complementary Technologies

      • Next-Generation Oral Selective TYK2 Inhibitors (Sotyktu Follow-Ons, PF-06826647 — Pfizer)

      • Bispecific Antibodies Targeting Dual Cytokine Pathways (Anti-IL-17A/IL-36R Bispecific)

      • IL-36 Receptor Inhibitors for Generalized Pustular Psoriasis (Spesolimab — SPEVIGO — Boehringer Ingelheim; Imsidolimab — Phase 3)

      • Nano-Formulation Topical Drug Delivery Systems for Enhanced Skin Penetration

      • mRNA-Based Immunomodulatory Therapies for Psoriasis (Early-Stage Research)

      • AI-Powered Precision Dermatology — Genomic Biomarker-Guided Biologic Selection

      • Izokibep — Small IL-17A Protein Inhibitor (Phase 2/3 — ACELYRIN, INC.)

      • SDC-1801 — Novel Oral TYK2/JAK1 Inhibitor (Sareum Holdings, Phase 1 — Approved by TGA Australia, May 2023)

  • 3.5 Patent Analysis

    • 3.5.1 Patent Publication Trends in Psoriasis Biologic Drug Molecules & Formulation Technologies

    • 3.5.2 Jurisdiction Analysis & Top Applicants (AbbVie, J&J, Novartis, BMS, Eli Lilly)

    • 3.5.3 Patent Cliff Analysis — Key Biologic Drug Exclusivity Expirations (Stelara, Enbrel, Humira Biosimilar Impact 2023–2028)

  • 3.6 Pipeline Analysis

    • 3.6.1 Late-Stage Clinical Pipeline (Phase 3 Candidates by Disease Indication)

      • Plaque Psoriasis: Izokibep (ACELYRIN, IL-17A — Phase 2/3); JNJ-77242113 (J&J IL-23p19 — Phase 3); Spesolimab Maintenance for GPP (Boehringer Ingelheim — Phase 3)

      • Psoriatic Arthritis: Imsidolimab (IL-36R — Phase 3); PF-06826647 (Pfizer TYK2 — Phase 3); TLL-018 (Anti-IL-23 — Phase 2)

      • Pediatric Psoriasis: Zoryve Cream Indication Expansion for Ages 6–11 (FDA Approved October 2023)

    • 3.6.2 Early-Stage Pipeline (Phase 1 & Phase 2 Candidates)

    • 3.6.3 Unmet Clinical Need by Psoriasis Type & Regulatory Incentive Programs (Orphan Drug, Fast Track, BTD)

  • 3.7 Regulatory Landscape & Compliance Framework

    • 3.7.1 United States — FDA Regulatory Framework for Psoriasis Biologics & Small Molecules

      • BLA (Biologic License Application) & NDA Pathways for Psoriasis Drugs

      • Biosimilar Approval Pathway (351(k) BPCIA) & Interchangeability Designation

      • FDA Breakthrough Therapy Designation (BTD) & Priority Review for IL-36 & TYK2 Agents

      • Inflation Reduction Act (IRA) Impact — Enbrel & Stelara Included in Medicare Price Negotiations (August 2023)

      • FDA Draft Guidance — Developing Drugs for Moderate-to-Severe Plaque Psoriasis (PASI 75/90/100 as Primary Endpoints)

    • 3.7.2 European Union — EMA Approval Framework & European Commission Marketing Authorizations

      • Sotyktu EC Approval for Moderate-to-Severe Plaque Psoriasis (March 2023 — BMS)

      • Cosentyx IV Formulation EC Approval (Novartis — PsA & Psoriasis)

      • EU Biosimilar Adalimumab Transition Post-Humira LOE (2023)

    • 3.7.3 Japan — MHLW Approval Framework (Bimzelx Authorization for Plaque Psoriasis, Psoriatic Erythroderma & Pustular Psoriasis — UCB S.A.)

    • 3.7.4 China (NMPA) — Priority Review Category for Psoriasis Biologics & Clinical Trial Registration Requirements

    • 3.7.5 India (CDSCO) — New Drugs & Clinical Trials Rules 2019 for Psoriasis Therapeutics

    • 3.7.6 Health Canada — New Drug Submission (NDS) Review for Roflumilast Cream (Arcutis — Accepted July 2022)

    • 3.7.7 Key Regulatory Bodies & Global Standards Harmonization

      • ICH E9/E10 (Statistical Principles & Active Comparator Design for Psoriasis Trials)

      • GRAPPA Guidelines (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis)

      • EULAR Recommendations for PsA Management

  • 3.8 Pricing Analysis

    • 3.8.1 Biologic Psoriasis Drug Pricing Benchmarking (WAC, ASP & Out-of-Pocket Cost)

      • Annual Biologic WAC Range: USD 40,000–90,000 (IL-17, IL-23 Agents — U.S.)

      • Out-of-Pocket Biologics: USD 4,423–USD 6,950/Year (NCBI 2021 Reference)

      • Topical Medication Cost: USD 500–600 per Tube (NPF Data)

    • 3.8.2 Biosimilar Adalimumab Impact on Pricing (Yusimry, Hadlima, Hyrimoz — USD 2,000–5,000/Year Tiered Pricing)

    • 3.8.3 Regional Price Variation — U.S. vs. EU vs. Asia Pacific Biologic Drug Pricing Dynamics

    • 3.8.4 Value-Based & Outcome-Based Pricing Models for Novel Psoriasis Biologics

  • 3.9 Reimbursement Landscape

    • 3.9.1 U.S. Medicare & Medicaid Biologic Psoriasis Drug Reimbursement (IRA Part D Negotiation Impact — Enbrel & Stelara)

    • 3.9.2 U.S. Commercial Insurance & PBM Formulary Positioning for Psoriasis Biologics (Step Therapy, Prior Authorization)

    • 3.9.3 European NHS, GKV (Germany) & Social Insurance Reimbursement Coverage for Advanced Psoriasis Treatments (HTA Assessment by NICE, HAS, IQWIG)

    • 3.9.4 Asia Pacific Government Reimbursement Trends (China NRDL, Japan NHI, India PMJAY Coverage)

  • 3.10 Key Conferences & Industry Events (2026–2027)

    • 3.10.1 AAD (American Academy of Dermatology) Annual Meeting

    • 3.10.2 EADV (European Academy of Dermatology & Venereology) Annual Congress

    • 3.10.3 GRAPPA (Group for Research and Assessment of Psoriasis and PsA) Annual Meeting

    • 3.10.4 EULAR (European League Against Rheumatism) Annual Congress

    • 3.10.5 World Psoriasis Day (October 29) & National Psoriasis Foundation Summit

  • 3.11 Unmet Needs in the Psoriasis Treatment Market

    • 3.11.1 Functional Cure or Long-Term Complete Remission for Moderate-to-Severe Plaque Psoriasis

    • 3.11.2 Effective Oral Therapies Matching Biologic Efficacy with Improved Patient Convenience

    • 3.11.3 Safe & Effective Treatments for Pediatric, Elderly & Pregnancy-Related Psoriasis

    • 3.11.4 Affordable Treatment Access in Low- and Middle-Income Countries (LMICs)

    • 3.11.5 Precision Medicine — Biomarker-Driven Patient Selection for Biologic Therapy Optimization

  • 3.12 End-User Expectations & Key Buying Criteria

    • 3.12.1 Clinical Efficacy (PASI 90/100 Achievement Rates)

    • 3.12.2 Speed of Onset, Durability of Response & Long-Term Safety Profile

    • 3.12.3 Dosing Convenience (Oral vs. SC vs. IV; Weekly vs. Monthly vs. Quarterly Schedules)

    • 3.12.4 Reimbursement Coverage & Patient Co-Pay Support Program Availability

  • 3.13 AI & Digital Technology Integration in Psoriasis Treatment

    • 3.13.1 AI-Powered Dermatology Diagnostic Apps & Teledermatology Platforms (DermEngine, SkinVision)

    • 3.13.2 AI-Guided Biologic Selection & Personalized Treatment Protocol Optimization

    • 3.13.3 Digital Adherence Monitoring Tools & Patient Engagement Apps for Chronic Psoriasis Management

  • 3.14 Impact of Macroeconomic & Geopolitical Factors

    • 3.14.1 Rising Global Psoriasis Prevalence — 125 Million People Affected Worldwide (NPF 2023 Data)

    • 3.14.2 Inflation Reduction Act (IRA) Impact on Biologic Drug Pricing & Market Access in the U.S.

    • 3.14.3 Supply Chain Challenges in Biologic Drug Manufacturing (CHO Cell Lines, Cold-Chain Logistics)

    • 3.14.4 Post-COVID-19 Resurgence in Dermatology Clinic Visits & Increased Telemedicine Prescription Volumes

4. Market Dynamics

  • 4.1 Market Drivers

    • 4.1.1 Rising Global Prevalence of Psoriasis (125 Million People Worldwide — NPF 2023; 8 Million+ in the U.S.)

    • 4.1.2 Growing Adoption of Biologic Therapies (IL-17, IL-23, TYK2 Inhibitors) Delivering Superior Efficacy Outcomes

    • 4.1.3 Increasing R&D Investment in Next-Generation Oral & Biologic Psoriasis Drug Development

    • 4.1.4 Favorable Regulatory Environment — Fast Track, BTD & Priority Review Accelerating Novel Drug Approvals

    • 4.1.5 Expanding Biosimilar Portfolio Improving Treatment Affordability & Market Access (Yusimry — Coherus BioSciences, December 2021 FDA Approval)

    • 4.1.6 Growing Awareness Programs Improving Early Diagnosis & Treatment Initiation (AAD–Boehringer Ingelheim GPP Education Program, June 2023)

    • 4.1.7 Increasing Strategic Collaborations, Acquisitions & Product Launches Among Key Biopharmaceutical Players

    • 4.1.8 Post-COVID-19 Surge in Telemedicine Enabling Greater Psoriasis Management Outreach

  • 4.2 Market Restraints

    • 4.2.1 High Cost of Biologic & Advanced Psoriasis Treatments Limiting Access (Biologics: USD 40,000–90,000/Year WAC in the U.S.)

    • 4.2.2 Lack of Favorable Reimbursement & Insurance Coverage in Developing Nations

    • 4.2.3 Risk of Adverse Events Associated with Long-Term Biologic & JAK Inhibitor Use (Immunosuppression, Infections, Malignancy Risk)

    • 4.2.4 Patent Expiries & Biosimilar Competition Eroding Revenue of Branded Biologic Leaders (Humira LOE, 2023)

  • 4.3 Market Opportunities

    • 4.3.1 Development of First-Oral Biologic-Level Efficacy Drugs (Deucravacitinib TYK2 Inhibitor Class Expansion)

    • 4.3.2 Untapped Emerging Markets — Asia Pacific (China, India), Latin America, Middle East & Africa

    • 4.3.3 Precision Medicine & AI-Based Biomarker-Driven Patient Stratification for Biologic Selection

    • 4.3.4 Pediatric & Geriatric Psoriasis Indication Expansions Broadening Patient Population

    • 4.3.5 IL-36R Inhibitors Addressing Generalized Pustular Psoriasis (GPP) Orphan Disease Gap (SPEVIGO — Boehringer Ingelheim)

  • 4.4 Market Challenges

    • 4.4.1 Complex Step Therapy, Prior Authorization & PBM Formulary Restrictions Delaying Advanced Biologic Access

    • 4.4.2 Managing Psoriasis Comorbidities (Psoriatic Arthritis, Cardiovascular Disease, IBD, Depression) Requiring Multi-Specialty Coordination

  • 4.5 Porter's Five Forces Analysis

    • 4.5.1 Bargaining Power of Suppliers (Biologic API & Monoclonal Antibody Manufacturing Concentration)

    • 4.5.2 Bargaining Power of Buyers (Insurance Payers, GPOs, Government Formularies)

    • 4.5.3 Threat of New Entrants (High Biologic R&D & Regulatory Barriers; Oral Small-Molecule Opportunity)

    • 4.5.4 Threat of Substitutes (Phototherapy, Conventional Systemics, Complementary Medicine)

    • 4.5.5 Intensity of Competitive Rivalry

  • 4.6 PESTLE Analysis

  • 4.7 Driver Impact Analysis (% Contribution to CAGR Forecast)

  • 4.8 Restraint Impact Analysis (% Impact on CAGR Forecast)

5. Psoriasis Treatment Market, By Drug Class

  • 5.1 Overview & Market Share Analysis

  • 5.2 TNF Inhibitors

    • 5.2.1 Market Size & Forecast (41.31% Market Share in 2026)

    • 5.2.2 Key Products & Applications

      • Adalimumab (Humira — AbbVie & Biosimilars: Yusimry, Hadlima, Hyrimoz, Cyltezo, Abrilada)

      • Etanercept (Enbrel — Amgen/Pfizer & Biosimilars)

      • Infliximab (Remicade — J&J & Biosimilars)

      • Certolizumab Pegol (Cimzia — UCB)

      • Golimumab (Simponi — J&J)

    • 5.2.3 Key Trends — Biosimilar Market Entry Post-Humira LOE (2023) Reshaping TNF Inhibitor Segment Dynamics

  • 5.3 Interleukin (IL) Inhibitors

    • 5.3.1 IL-12/23 Inhibitors (p40 & p19 Targeting)

      • Ustekinumab (Stelara — J&J) — IL-12/23 p40

      • Risankizumab (Skyrizi — AbbVie) — IL-23 p19

      • Guselkumab (Tremfya — J&J) — IL-23 p19

      • Tildrakizumab (Ilumya — Sun Pharma/LEO Pharma) — IL-23 p19

      • Mirikizumab (Omvoh — Eli Lilly) — IL-23 p19

      • Market Size & Forecast

      • Key Trends & Applications

    • 5.3.2 IL-17A / IL-17A+F Inhibitors

      • Secukinumab (Cosentyx — Novartis) — IL-17A; IV Formulation Approved October 2023

      • Ixekizumab (Taltz — Eli Lilly) — IL-17A

      • Bimekizumab (Bimzelx — UCB) — IL-17A & IL-17F Dual Inhibitor (FDA October 2023)

      • Market Size & Forecast

      • Key Trends & Applications

    • 5.3.3 IL-17 Receptor Inhibitors

      • Brodalumab (Siliq — AstraZeneca / Kyntheum — LEO Pharma) — IL-17RA

      • Market Size & Forecast

      • Key Trends & Applications

    • 5.3.4 IL-36 Receptor Inhibitors (GPP-Specific)

      • Spesolimab (SPEVIGO — Boehringer Ingelheim) — FDA Approved September 2022

      • Imsidolimab — Phase 3 (Anaptysbio)

      • Market Size & Forecast

      • Key Trends & Applications

  • 5.4 Others (JAK Inhibitors, TYK2 Inhibitors, PDE4 Inhibitors)

    • 5.4.1 Oral TYK2 Inhibitors

      • Deucravacitinib (Sotyktu — BMS) — First Oral TYK2 Inhibitor; EC Approved March 2023

      • Market Size & Forecast

      • Key Trends & Applications

    • 5.4.2 Oral JAK Inhibitors

      • Upadacitinib (Rinvoq — AbbVie) — JAK1 Selective; EC Approved for PsA January 2021

      • Tofacitinib (Xeljanz — Pfizer) — JAK1/3 for PsA

      • Market Size & Forecast

      • Key Trends & Applications

    • 5.4.3 PDE4 Inhibitors

      • Apremilast (Otezla — Amgen) — Oral PDE4 Inhibitor

      • Roflumilast (Zoryve — Arcutis) — Topical PDE4 Inhibitor (Pediatric Expansion, Oct 2023)

      • Market Size & Forecast

      • Key Trends & Applications

6. Psoriasis Treatment Market, By Type (Disease Indication)

  • 6.1 Overview & Market Share Analysis

  • 6.2 Plaque Psoriasis

    • 6.2.1 Market Size & Forecast (41.31% Global Share in 2026; 80–90% of All Psoriasis Cases)

    • 6.2.2 Mild-to-Moderate Plaque Psoriasis (BSA <10%, PASI <10)

      • Key Treatments — Topical Corticosteroids, Vitamin D Analogues, Roflumilast Cream, Phototherapy

      • Market Size & Forecast

      • Key Trends & Applications

    • 6.2.3 Moderate-to-Severe Plaque Psoriasis (BSA ≥10%, PASI ≥10 or High DLQI)

      • Key Treatments — IL-17, IL-23, TYK2 & TNF Biologic Therapies; Oral Systemics

      • Market Size & Forecast

      • Key Trends & Applications

  • 6.3 Psoriatic Arthritis (PsA)

    • 6.3.1 Market Size & Forecast (Fastest-Growing Type Segment — 30%–40% of Psoriasis Patients Develop PsA)

    • 6.3.2 Key Treatments — TNF Inhibitors, IL-17A Inhibitors (Cosentyx IV — Novartis October 2023), JAK Inhibitors (Rinvoq), TYK2 (Sotyktu), PDE4 (Otezla)

    • 6.3.3 Key Trends & Applications (NIH AMP AIM Grant — USD 58.5 Million for PsA Research, March 2022)

  • 6.4 Others

    • 6.4.1 Pustular Psoriasis (Generalized — GPP; Palmoplantar — PPP)

      • SPEVIGO (Spesolimab) — First FDA-Approved GPP Treatment (September 2022)

      • Market Size & Forecast

      • Key Trends & Applications

    • 6.4.2 Erythrodermic Psoriasis

      • Bimzelx (Bimekizumab) — MHLW Approved for Psoriatic Erythroderma (January 2022)

      • Market Size & Forecast

      • Key Trends & Applications

    • 6.4.3 Guttate & Inverse Psoriasis

      • Market Size & Forecast

      • Key Trends & Applications

7. Psoriasis Treatment Market, By Product Type

  • 7.1 Overview & Market Share Analysis

  • 7.2 Biologics

    • 7.2.1 Market Size & Forecast (90.73% Market Share in 2026)

    • 7.2.2 Monoclonal Antibody-Based Biologics

      • Market Size & Forecast

      • Key Trends (Subcutaneous, IV & Long-Acting Formulation Innovations)

    • 7.2.3 Biosimilars (Adalimumab Biosimilars — Yusimry, Hadlima, Cyltezo, Hyrimoz, Abrilada)

      • Market Size & Forecast

      • Key Trends (CMS Medicare Biosimilar Interchange, Mark Cuban Cost Plus Drug Company Collaboration — June 2023)

  • 7.3 Non-Biologics

    • 7.3.1 Oral Systemic Drugs (Methotrexate, Cyclosporine, Acitretin, Apremilast, Deucravacitinib, Upadacitinib)

      • Market Size & Forecast

      • Key Trends & Applications

    • 7.3.2 Topical Therapies (Corticosteroids, Vitamin D Analogues, Calcineurin Inhibitors, Roflumilast Cream, Coal Tar)

      • Market Size & Forecast

      • Key Trends & Applications

    • 7.3.3 Phototherapy (Narrowband UVB, PUVA, Excimer Laser)

      • Market Size & Forecast

      • Key Trends & Applications

8. Psoriasis Treatment Market, By Route of Administration

  • 8.1 Overview & Market Share Analysis

  • 8.2 Parenteral / Systemic

    • 8.2.1 Market Size & Forecast (83.48% Market Share in 2026)

    • 8.2.2 Subcutaneous Injection (Pre-filled Syringes & Auto-Injectors — Standard Biologic Delivery)

      • Market Size & Forecast

      • Key Trends & Applications

    • 8.2.3 Intravenous (IV) Infusion (Infliximab; Cosentyx IV — Novartis, FDA Approved October 2023)

      • Market Size & Forecast

      • Key Trends & Applications

  • 8.3 Oral

    • 8.3.1 Market Size & Forecast (Fastest-Growing Route — Deucravacitinib, Apremilast, Upadacitinib, Tofacitinib)

    • 8.3.2 Key Trends & Applications (Patient Compliance, Oral Convenience vs. Self-Injection Preference)

  • 8.4 Topical

    • 8.4.1 Market Size & Forecast

    • 8.4.2 Key Trends & Applications (Corticosteroids, Calcineurin Inhibitors, Roflumilast Cream, Vitamin D Analogues)

9. Psoriasis Treatment Market, By Distribution Channel

  • 9.1 Overview & Market Share Analysis

  • 9.2 Hospital Pharmacies

    • 9.2.1 Market Size & Forecast

    • 9.2.2 Key Trends & Demand Drivers (IV Biologic Infusion Administration, Hospital-Based Specialty Care)

  • 9.3 Retail Pharmacies

    • 9.3.1 Market Size & Forecast (Largest Segment — Driven by Independent & Chain Pharmacies in Emerging Markets)

    • 9.3.2 Key Trends & Demand Drivers (Reliance Retail — 2,000 Standalone India Pharmacy Launch, January 2023)

  • 9.4 Online Pharmacies

    • 9.4.1 Market Size & Forecast (Fastest-Growing Channel)

    • 9.4.2 Key Trends & Demand Drivers (Mark Cuban Cost Plus Drug Company–Coherus YUSIMRY Collaboration, June 2023)

10. Psoriasis Treatment Market, By Region

  • 10.1 Overview & Market Share Analysis

  • 10.2 North America

    • 10.2.1 Market Size & Forecast (74.83% Global Revenue Share in 2025)

    • 10.2.2 United States (USD 21.75 Billion by 2026 — 8 Million+ Psoriasis Patients)

    • 10.2.3 Canada

    • 10.2.4 Mexico

  • 10.3 Europe

    • 10.3.1 Market Size & Forecast (13.77% Global Share in 2025; USD 4.33 Billion by 2026)

    • 10.3.2 Germany (USD 1.05 Billion by 2026)

    • 10.3.3 United Kingdom (USD 0.63 Billion by 2026; Prevalence 1.3–2.2%)

    • 10.3.4 France

    • 10.3.5 Italy

    • 10.3.6 Spain

    • 10.3.7 Scandinavia (Denmark, Sweden, Norway)

    • 10.3.8 Rest of Europe

  • 10.4 Asia Pacific

    • 10.4.1 Market Size & Forecast (6.98% Share in 2025; Fastest-Growing Region)

    • 10.4.2 Japan (USD 0.61 Billion by 2026)

    • 10.4.3 China (USD 0.74 Billion by 2026)

    • 10.4.4 India (USD 0.27 Billion by 2026)

    • 10.4.5 South Korea

    • 10.4.6 Australia & New Zealand (SDC-1801 TGA Phase 1 Approval, May 2023)

    • 10.4.7 Rest of Asia Pacific

  • 10.5 Latin America

    • 10.5.1 Market Size & Forecast (USD 0.79 Billion by 2026; Prevalence 1.27–1.56% — WHO)

    • 10.5.2 Brazil

    • 10.5.3 Mexico

    • 10.5.4 Argentina

    • 10.5.5 Rest of Latin America

  • 10.6 Middle East & Africa

    • 10.6.1 Market Size & Forecast (USD 0.56 Billion by 2026; 1.84% Global Share)

    • 10.6.2 GCC Countries (Saudi Arabia, UAE, Kuwait)

    • 10.6.3 South Africa

    • 10.6.4 Rest of Middle East & Africa

11. Competitive Landscape

  • 11.1 Market Share Analysis of Key Players (Highly Consolidated — J&J and AbbVie Leading with Largest Share)

  • 11.2 Market Concentration & Competitive Characteristics

  • 11.3 Company Evaluation Matrix — Key Players (2026)

    • 11.3.1 Stars (Dominant Full-Portfolio Biologic Psoriasis Leaders — AbbVie, J&J, Novartis, Eli Lilly)

    • 11.3.2 Emerging Leaders (High-Growth Oral & TYK2 Innovators — BMS Sotyktu, Boehringer Ingelheim SPEVIGO)

    • 11.3.3 Pervasive Players (Specialty Biologic Competitors — UCB Bimzelx, Arcutis, LEO Pharma)

    • 11.3.4 Participants (Biosimilar & Generic Manufacturers, Early-Stage Biotech — ACELYRIN, Sareum)

  • 11.4 Competitive Benchmarking Matrix (by Drug Class, Indication Coverage, Pipeline Depth, Geography & Revenue)

  • 11.5 Heat Map Analysis

  • 11.6 Market Positioning of Key Players (2026)

  • 11.7 Strategic Developments & Recent Initiatives

    • 11.7.1 Mergers & Acquisitions

      • Nimbus Therapeutics TYK2 Program — USD 125.0 Million Funding (September 2022)

      • NIH AMP AIM Grant — USD 58.5 Million for PsA Research Across Multiple Institutions (March 2022)

    • 11.7.2 Collaborations, Partnerships & Licensing Agreements

      • AAD–Boehringer Ingelheim GPP Awareness & Education Program (June 2023)

      • Coherus BioSciences–Mark Cuban Cost Plus Drug Company (YUSIMRY Biosimilar Distribution, June 2023)

    • 11.7.3 Product Launches & Regulatory Approvals

      • UCB BIMZELX — FDA Approval for Moderate-to-Severe Plaque Psoriasis (October 2023)

      • BMS Sotyktu — EU EC Approval for Moderate-to-Severe Plaque Psoriasis (March 2023)

      • Boehringer Ingelheim SPEVIGO — FDA Approval for GPP (September 2022)

      • Arcutis Zoryve Cream — FDA sNDA Approval for Ages 6–11 Pediatric Plaque Psoriasis (October 2023)

      • Novartis Cosentyx IV — FDA Approval for PsA & Psoriasis (October 2023)

    • 11.7.4 Expansions & Investments

      • CMS Inflation Reduction Act Medicare Price Negotiation — Enbrel & Stelara Inclusion (August 2023)

      • Asia Pacific Manufacturing & Distribution Network Expansion by Novartis, AbbVie & Eli Lilly

12. Company Profiles (The final report includes a complete list of companies)

  • 12.1 AbbVie Inc.

    • 12.1.1 Company Overview

    • 12.1.2 Financial Performance

    • 12.1.3 Product Portfolio

    • 12.1.4 Strategic Initiatives

    • 12.1.5 SWOT Analysis

  • 12.2 Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals)

  • 12.3 Novartis AG

  • 12.4 Eli Lilly and Company

  • 12.5 Bristol-Myers Squibb Company

  • 12.6 Pfizer Inc.

  • 12.7 UCB S.A.

  • 12.8 Amgen Inc.

  • 12.9 Boehringer Ingelheim International GmbH

  • 12.10 Merck & Co., Inc.

  • 12.11 LEO Pharma A/S

  • 12.12 Sun Pharmaceutical Industries Ltd.

  • 12.13 Arcutis Biotherapeutics, Inc.

  • 12.14 AstraZeneca plc

  • 12.15 Coherus BioSciences, Inc.

13. Investment Analysis

  • 13.1 Investment Landscape Overview

  • 13.2 Mergers & Acquisitions Trend Analysis

  • 13.3 Venture Capital & Private Equity Funding Trends in Psoriasis Drug Development

  • 13.4 Key Investment Opportunities by Region & Drug Class

14. Future Market Outlook & Emerging Trends

  • 14.1 Trends & Disruptions Impacting Customers' Businesses

    • 14.1.1 Accelerating Shift from Parenteral Biologics to Convenient Oral Biologic-Level Efficacy Therapies (TYK2 & Oral IL Inhibitors)

    • 14.1.2 Transition Toward Treat-to-Target (T2T) & PASI 100 Achievement as New Standard of Care

  • 14.2 Emerging Technologies Reshaping Psoriasis Treatment

    • 14.2.1 Next-Generation Oral TYK2 Selective Inhibitors with Improved Safety & Tolerability Profiles

    • 14.2.2 Bispecific Antibodies Targeting Dual IL Cytokine Pathways (Anti-IL-17A/IL-36R; Anti-IL-23/IL-17)

    • 14.2.3 AI-Powered Genomic Biomarker Profiling for Precision Biologic Selection & Response Prediction

    • 14.2.4 IL-36R Inhibitor Class Expansion from GPP to PPP, PsA & Other Orphan Psoriasis Subtypes

    • 14.2.5 mRNA Immunomodulatory Therapeutics for Psoriasis — Early-Stage Research & Pre-Clinical Programs

    • 14.2.6 Nano-Formulation Advanced Topical Delivery Systems Improving Drug Penetration & Localized Efficacy

    • 14.2.7 Digital Dermatology Platforms — AI Skin Imaging, Teledermatology & Remote PASI Scoring Tools

    • 14.2.8 Functional Cure Research — Long-Term Remission-Inducing Biologic & Cell Therapy Strategies

    • 14.2.9 Pediatric Psoriasis Treatment Innovation — FDA/EMA Indication Expansions for Children & Adolescents

    • 14.2.10 Microbiome & Skin Barrier Repair Adjunctive Therapy Development Alongside Core Anti-Psoriatic Drugs

  • 14.3 Future Market Projections (2026–2033)

  • 14.4 Strategic Recommendations for Market Participants

15. Appendix

  • 15.1 Research Methodology

  • 15.2 Data Triangulation & Validation

  • 15.3 List of Tables & Figures

  • 15.4 List of Abbreviations & Acronyms

  • 15.5 About the Publisher

16. Disclaimer

Enhance your decision-making capabilities with a 5 Reports-in-1
Bundle deal for - more than 40% off!

Our professional analysts will provide you with immediate assistance.